New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 19, 2014
14:52 EDTNKTR, AZNAstraZeneca says data demonstrate naloxegol improved OIC in pain patients
AstraZeneca announced that the New England Journal of Medicine has published results of two pivotal Phase III studies KODIAC-4 and KODIAC-5 of naloxegol, an investigational treatment for opioid-induced constipation, or OIC. Primary endpoint data from the KODIAC-4 and -5 studies showed that more OIC patients treated with naloxegol 25 mg had a consistent response of increased spontaneous bowel movements through 12 weeks of treatment compared to placebo. The 12.5 mg dose in KODIAC-5 did not show statistical significance for the primary endpoint. The 25 mg dose also demonstrated a higher response rate through 12 weeks of treatment compared to placebo in patients with laxative inadequate response, a secondary endpoint. Results for an additional secondary endpoint showed that patients taking naloxegol 25 mg in the KODIAC-4 and KODIAC-5 studies were likely to have a first post-dose spontaneous bowel movement 25-30 hours sooner than placebo, respectively. A New Drug Application for naloxegol was accepted by the U.S. Food and Drug Administration in November 2013. MOVANTIK is the proposed proprietary name for naloxegol. Nektar Therapeutics (NKTR) is partnering with AstraZeneca on naloxegol.
News For AZN;NKTR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2015
07:31 EDTAZNLeerink to hold a roundtable
Subscribe for More Information
September 30, 2015
08:02 EDTAZNAstraZeneca says SYMBICORT results published in journal
Subscribe for More Information
September 29, 2015
08:07 EDTAZNAstraZeneca says Brilinta 60-mg tablets now available in U.S. pharmacies
Subscribe for More Information
September 28, 2015
07:52 EDTAZNIIR Holdings to hold a conference
Subscribe for More Information
September 25, 2015
07:22 EDTAZNEuropean Society for Medical Oncology to hold a conference
Subscribe for More Information
September 22, 2015
08:02 EDTAZNAstraZeneca to present 33 abstracts from respiratory disease portfolio at ERS
Subscribe for More Information
07:43 EDTAZNDrug stocks could be hurt by focus on pricing, says Oppenheimer
Subscribe for More Information
07:17 EDTAZNAstraZeneca eyes crowd sourcing for better cancer drug cocktails, Reuters says
AstraZeneca's decision release preclinical data from over 50 of its medicines is "unprecedented" in scale and will speed up the hunt for tumor-fighting drug combinations, Reuters says. The company is aiming for a crowd sourcing initiative to help mix the future's cancer drug cocktails, the report says. Reference Link
06:19 EDTAZNClinton to roll out plan to rein in prescription drug costs, USA Today reports
Subscribe for More Information
September 21, 2015
14:28 EDTAZNTuring CEO says will not change Daraprim price despite criticism
Subscribe for More Information
11:24 EDTAZNHillary Clinton vows to take on 'outrageous' specialty drug pricing
Hillary Clinton, on the heels of a Wall Street Journal report detailing Turing Pharmaceuticals' price hike to $750 from $13.50 per pill of a drug called Daraprim which treats a life-threatening parasitic infection, vowed to lay out a plan tomorrow to take on what she calls "price gouging" of specialty drugs. The presidential nominee stated in a tweet, "Price gouging like this in the specialty drug market is outrageous. Tomorrow I'll lay out a plan to take it on." The iShares Nasdaq Biotechnology Index (IBB) moved lower following Clinton's tweet.
09:02 EDTNKTRNektar presents data from study of NKTR-214
Nektar announced positive preclinical results for NKTR-214, a CD122-biased cytokine designed to preferentially stimulate the production and maintenance of tumor-killing T cells which are found naturally in the body. CD122, which is also known as the Interleukin-2 receptor beta subunit, is a key signaling receptor that is known to increase the proliferation of CD8-positive effector T cells, and these CD8-positive T cells comprise a key component of the tumor infiltrating lymphocytes that provide cell-mediated anti-tumor effects. Results were presented this past Friday at the Inaugural CRI-CIMT-EATI-AACR Immunotherapy Conference in New York. NKTR-214 shows efficacy in multiple preclinical models as a single agent. Combination regimens with NKTR-214 and either anti-CTLA4 or anti-PD-1 checkpoint inhibitor therapies resulted in durable anti-tumor immunotherapeutic effects, which persisted long after the termination of dosing.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use